The company is also working with Novo Nordisk under separate license agreements to develop GlycoPEGylated versions of recombinant Factors VIIa and VIII. A Phase I trial of GlycoPEG-Factor VIIa is currently ongoing.
George Vergis, president and CEO of Neose, said: “We are excited about Novo Nordisk’s continued progress in developing a long-acting Factor IX using our GlycoPEGylation technology.”